消息面上，北海康成此前宣布，向药明生物旗下子公司配售8,403.36万股股份，占扩大后股本约 14.12%。配股事项所得款项净额约1.99亿港元，约12%将用于商业化产品的营运资金及注册维护；28% 用于现有产品线的研发开支；60%用于结算集团的贸易应付款项。配售完成后，药明生物于北海康成的 持股比例将升至约16.27%。 智通财经获悉，北海康成-B(01228)午后涨超6%，截至发稿，涨5.68%，报2.79港元，成交额172.27万港 元。 本文源自：智通财经网 ...

每经AI快讯，北海康成-B(01228.HK)午后一度涨超6%，截至发稿涨5.68%，报2.79港元，成交额172.27 万港元。 ...

北海康成-B(01228)午后涨超6%，截至发稿，涨5.68%，报2.79港元，成交额172.27万港元。 消息面上，北海康成此前宣布，向药明生物旗下子公司配售8,403.36万股股份，占扩大后股本约 14.12%。配股事项所得款项净额约1.99亿港元，约12%将用于商业化产品的营运资金及注册维护；28% 用于现有产品线的研发开支；60%用于结算集团的贸易应付款项。配售完成后，药明生物于北海康成的 持股比例将升至约16.27%。 ...

消息面上，北海康成此前宣布，向药明生物旗下子公司配售8,403.36万股股份，占扩大后股本约 14.12%。配股事项所得款项净额约1.99亿港元，约12%将用于商业化产品的营运资金及注册维护；28% 用于现有产品线的研发开支；60%用于结算集团的贸易应付款项。配售完成后，药明生物于北海康成的 持股比例将升至约16.27%。 智通财经APP获悉，北海康成-B(01228)午后涨超6%，截至发稿，涨5.68%，报2.79港元，成交额172.27 万港元。 ...

张玮航 国联民生证券医药分析师: 各位投资者，大家这个上午好。那个开年第一天，大家开工大吉。那首先感谢大家来参加 我们国联民生。医药团队的这个电话会，今天是那个北海康成的这个近期情况的更新的电 话会议。我是那个，就是国内民生的研究员张金阳，在线跟我一起主持的还有我们团队的 胡若冰胡博，还有那个郭王洋。那节前，我们团队也组织了在康城的这个电话会，当时是 从这个罕见病行业的角度，这个当时这个邀请了薛总和百洋的这个副总来跟大家做了一个 沟通。那今天，这个电话会的主要的这个内容，是盖康城其实在春节期间，我们看到了一 个公告，这个配收了这个 8400 万股的这个股份给这个药明生物子公司，募集了 2 亿港元。 这个公告里面这个说这 2 亿港元的 12%用于商业化这个产品的运营。28%用于这个管线 的这个研发开支，60%用于这个结算集团的贸易应付款，那也，这个另外也补充公告了这 个售出现有股票的这个单位，其中一名服务供应商向本集团提供发展这个策略咨询，而另 一名的这个服务供应商就是，就要药物监管审批事宜，向本集团提供这个监管咨询，这些 相关的公告内容，我相信大家也看到了。那我们今天，针对这件事，也是很荣幸的再次请 到了这个 ...

本公司謹此補充說明兩名服務供應商購股權承授人及兩名服務供應商受限制股份單位承授人之相 關資訊（此兩名承授人為同一人士）。其中一名服務供應商向本集團提供發展策略諮詢（「服務供應商 1」），而另一名服務供應商則就藥物監管審批事宜向本集團提供監管諮詢（「服務供應商2」）。 鑒於服務供應商1長期支援本集團的研發策略及活動，而服務供應商2則於本集團藥物監管審批過程 中提供諮詢服務，董事會認為向彼等授出購股權及受限制股份單位符合相關計劃目的，即與按持續 或經常性基準提供服務的服務供應商的利益與本集團的長期發展的利益保持一致。此等授出反映彼 等長期為本集團提供服務，以及該等服務對本集團業務、增長及發展的重要性。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 CANbridge Pharmaceuticals Inc. 北海康成製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1228） 有關授出購股權及受限制股份單位的補充公告 茲提述北海康成製藥有限公 ...

Group 1 - The core point of the article is that Beihai Kangcheng-B (01228) experienced a significant stock price increase, rising over 17% at one point and closing up 8.6% at HKD 3.03, with a trading volume of HKD 26.6484 million [1] - On February 16, Beihai Kangcheng announced a placement of 84.0336 million new shares to a wholly-owned subsidiary of WuXi Biologics, representing approximately 14.12% of the company's enlarged issued share capital, at a price of HKD 2.38 per share, which is a discount of about 14.7% compared to the closing price of HKD 2.79 on February 13 [1] - The net proceeds from the placement are expected to reach HKD 199 million, with approximately 60% allocated for settling the group's trade payables, around 28% for research and development expenses for existing product lines, and the remaining 12% for working capital and regulatory maintenance of commercialized products [1]

Group 1 - The core point of the article is that Beihai Kangcheng-B (01228) announced a share placement to WuXi Biologics, leading to a significant increase in its stock price [1] - The company plans to issue 84.03 million new shares, representing approximately 14.12% of the enlarged issued share capital, at a price of HKD 2.38 per share, which is a discount of about 14.7% compared to the closing price of HKD 2.79 on February 13 [1] - The net proceeds from the placement are expected to reach HKD 199 million, with around 60% allocated for settling trade payables, approximately 28% for R&D expenses of existing product lines, and the remaining 12% for working capital and regulatory maintenance of commercialized products [1] Group 2 - Following the completion of the placement, WuXi Biologics' stake in Beihai Kangcheng will increase to approximately 16.27% [1]

Group 1 - The core point of the article is that Beihai Kangcheng-B (01228.HK) experienced an 11% increase in stock price following the announcement of a new share issuance at a nearly 15% discount to WuXi Biologics' subsidiary [1] Group 2 - The company is issuing new shares to a subsidiary of WuXi Biologics, indicating a strategic partnership or investment [1] - The discount of nearly 15% on the new shares suggests a significant valuation consideration in the transaction [1] - The stock price reaction of an 11% increase reflects positive market sentiment towards the company's decision [1]

Core Viewpoint - North Sea Kangcheng-B (01228.HK) has entered into a subscription agreement with WuXi Biologics HealthCare Venture, agreeing to issue and the subscriber agreeing to purchase a total of 84.036 million subscription shares at a price of HKD 2.38 per share, representing approximately 16.44% of the existing issued shares as of the announcement date [1] Group 1 - The total amount raised from the subscription is expected to be approximately HKD 200 million, with the estimated net proceeds from the subscription being around HKD 199 million [1] - The company plans to use the net proceeds for (i) working capital and regulatory maintenance for commercialized products; (ii) research and development expenses for existing product lines; and (iii) settling trade payables of the group [1]